Source: Eur Respir J 2009; 34: 1364-1375
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Stolz D., Smyrnios N., Eggimann P., Pargger H., Thakkar N., Siegemund M., Marsch S., Azzola A., Rakic J., Mueller B., Tamm M.. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34: 1364-1375

Member's Comments

No comment yet.

Related content which might interest you: Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients Source: Eur Respir J 2003; 22: 77S-83S Year: 2003 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 Optimising the duration of antibiotic therapy for ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 40-44 Year: 2007 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Aerosolised treatment for VAP Source: Eur Respir Mon 2011; 53: 54-65 Year: 2011 Impact of guidelines on HAP and VAP outcomes Source: Eur Respir Mon 2011; 53: 66-73 Year: 2011 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia Source: Eur Respir J 2008; 31: 356-362 Year: 2008 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia Source: Eur Respir J 2008; 32: 726-732 Year: 2008 Predictive value of procalcitonin in ventilator-associated pneumonia Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Empiric antimicrobial therapy for ventilator-associated pneumonia after brain injury Source: Eur Respir J 2016; 47: 1219-1228 Year: 2016 Appropriateness and delay to initiate therapy in ventilator-associated pneumonia Source: Eur Respir J 2006; 27: 158-164 Year: 2006 Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 Reducing antibiotics use for ventilator-associated pneumonia in brain-injured patients Source: Eur Respir J 2016; 47: 1060-1061 Year: 2016 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008